The reconstructed self: understanding the private and public identity of a mother of a child with autism

Thesis (M.A.) University of Alaska Fairbanks, 2014The puzzle pattern of the autism awareness ribbon signifies the mystery of life on the spectrum. The spectrum is characterized by the wide range of possible diagnoses of autism. One family out of every 68 is affected by autism. Each shape and color of the puzzle illustrates the diversity of experience for each family and person living with autism. Therefore, the people living the everyday life of autism provide an insightful understanding of how the puzzle pieces fit together. The central focus of this research was the lived experience of the interviewees. Nine mothers of children diagnosed with autism were interviewed. Five themes emerged once the interviews were conducted: (a) public scrutiny, (b) family and friend responses, (c) mother versus society, (d) guilt and stress, and (e) advocacy and networking. Each of these themes represents the stories of mothers who live with children on the spectrum. Each story shared provides the reader with a deeper understanding of mothers' experiences who live with children on the spectrum

Multiple Myeloma Treatment in Real-world Clinical Practice : Results of a Prospective, Multinational, Noninterventional Study

Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: M.M. has received personal fees from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Sanofi, Novartis, and Takeda and grants from Janssen and Sanofi during the conduct of the study. E.T. has received grants from Janssen and personal fees from Janssen and Takeda during the conduct of the study, and grants from Amgen, Celgene/Genesis, personal fees from Amgen, Celgene/Genesis, Bristol-Myers Squibb, Novartis, and Glaxo-Smith Kline outside the submitted work. M.V.M. has received personal fees from Janssen, Celgene, Amgen, and Takeda outside the submitted work. M.C. reports honoraria from Janssen, outside the submitted work. M. B. reports grants from Janssen Cilag during the conduct of the study. M.D. has received honoraria for participation on advisory boards for Janssen, Celgene, Takeda, Amgen, and Novartis. H.S. has received honoraria from Janssen-Cilag, Celgene, Amgen, Bristol-Myers Squibb, Novartis, and Takeda outside the submitted work. V.P. reports personal fees from Janssen during the conduct of the study and grants, personal fees, and nonfinancial support from Amgen, grants and personal fees from Sanofi, and personal fees from Takeda outside the submitted work. W.W. has received personal fees and grants from Amgen, Celgene, Novartis, Roche, Takeda, Gilead, and Janssen and nonfinancial support from Roche outside the submitted work. J.S. reports grants and nonfinancial support from Janssen Pharmaceutical during the conduct of the study. V.L. reports funding from Janssen Global Services LLC during the conduct of the study and study support from Janssen-Cilag and Pharmion outside the submitted work. A.P. reports employment and shareholding of Janssen (Johnson & Johnson) during the conduct of the study. C.C. reports employment at Janssen-Cilag during the conduct of the study. C.F. reports employment at Janssen Research and Development during the conduct of the study. F.T.B. reports employment at Janssen-Cilag during the conduct of the study. The remaining authors have stated that they have no conflicts of interest. Publisher Copyright: © 2018 The AuthorsMultiple myeloma (MM) remains an incurable disease, with little information available on its management in real-world clinical practice. The results of the present prospective, noninterventional observational study revealed great diversity in the treatment regimens used to treat MM. Our results also provide data to inform health economic, pharmacoepidemiologic, and outcomes research, providing a framework for the design of protocols to improve the outcomes of patients with MM. Background: The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. Patients and Methods: Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. Results: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. Conclusion: The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.publishersversionPeer reviewe

Die Anwendung der Business Judgment Rule auf den GmbH-Geschäftsführer

Spätestens mit der Kodifizierung in § 93 Abs. 1 S. 2 AktG wurde die Business Judgment Rule als fester Bestandteil des deutschen Gesellschaftsrechts etabliert. Auch zugunsten der Geschäftsführer einer GmbH ist ein der aktienrechtlichen Regelung entsprechender unternehmerischer Ermessensfreiraum überwiegend anerkannt. Letzterem widmet sich die Arbeit vorwiegend im Wege der systematischen Übertragung der aktienrechtlichen Grundsätze. Als Basis werden zunächst die aktienrechtliche Regelungslage kritisch beleuchtet und Haftungssystem, Organisationsstruktur und Interessenlage in AG und GmbH gegenübergestellt. Diese Darstellung der Rahmenbedingungen mündet in die Synthese als Kern der Arbeit, wobei zunächst die sachliche und dogmatische Grundlage einer eigenständigen Business Judgment Rule im GmbH-Recht vertieft und daraufhin deren Tatbestandsmerkmale aufbereitet werden. Besonderes Augenmerk liegt auf dem Einfluss der Treuepflichten und der gesellschaftsvertraglichen Gestaltungsfreiheit.»The Application of the Business Jugdment Rule to the Managing Director of the GmbH«The doctrine of a Business Judgment Rule is codified in German corporate law in § 93 Abs. 1 S. 2 AktG concerning the Aktiengesellschaft (public corporation). The doctrine is generally considered to be applicable to the GmbH (closed corporation). On the basis of an analysis of the liability systems of the Aktiengesellschaft and the GmbH this dissertation conducts a transfer of the Business Judgment Rule-principles to the GmbH, emphasizing the GmbH-specific requirements in regard to the doctrine

Der Autoritatsbegriff in den Hauptphasen seiner historischen Entwicklung.

OPLADEN-RUG0

Rjosk S & Fritsche T (2024). PIA – the Police Investigation Assistant.

Law enforcement authorities struggle with a shortage of personnel and specialised staff. At the same time, police tasks become more extensive and complex. This development presents the police with a capacity challenge. We will discuss opportunities and requirements of generative AI deployment in police work and present PIA, the Police Investigation Assistant, as a proposed solution. PIA is a generative AI assistant that simplifies daily police work by taking over time-consuming and repetitive tasks. It provides support by processing information as required and writing reports, hence police officers can make better decisions and use their working time more effectively - more time for police work, less for administration.

Our fi&

copies of this thesis in microform, papa or electronic formats. The author retains ownership of the copyright in this thesis. Neither the thesis nor substantial extracts fiom it may be printed or otherwise reproduced without the author's permission. L'auteur a accordé une licence non exclusive permettant à la Bibliothèque nationale du Canada de reproduire, prêter, distribuer ou vendre des copies de cette thèse sous la forme de microfiche/film, de reproduction sur papier ou sur format électronique. L'auteur conserve la propriété du droit d'auteur qui protège cette thèse. Ni la thèse ni des extraits substantiels de celle-ci ne doivent être imprimés ou autrement reproduits sans so